



One North End Avenue ☿ Suite 1111 ☿ New York ☿ New York 10282  
Telephone: (877) 898-8038 (212) 791-2911 Fax: 212-791-2917

MEDIA CONTACT: Bill Berry, Berry & Co.: 212-253-8881  
INVESTOR RELATIONS CONTACT: Sean Collins, CCG – 310-477-9800, ext. 202

## **IMMTECH PHARMACEUTICALS NAMES DR. ZASLOFF AS ADVISOR**

New York, NY June 25, 2008 – Immtech Pharmaceuticals, Inc. (AMEX: IMM) today announced that Dr. Michael Zasloff has been named as special advisor to the Company. In this role Dr. Zasloff will conduct a review of Immtech’s drug development activities, including clinical research related to pafuramidine, a compound previously in development.

“Dr. Zasloff’s extensive experience in clinical research and drug development makes him a valuable addition to the Immtech team,” said Eric L. Sorkin, Chairman and Chief Executive Officer of Immtech. “With his achievements in all areas of clinical research, Dr. Zasloff is uniquely qualified to assess Immtech’s competitive advantages. We welcome Dr. Zasloff’s guidance, as well as his insights regarding opportunities to advance Immtech’s drug development program.”

“I am thrilled to join the Immtech team. The di-cationic class of anti-infectives Immtech has pioneered have significant promise as human therapeutics. I plan to contribute to Immtech’s efforts in fully realizing the medical and commercial potential of these compounds,” stated Dr. Zasloff.

Dr. Zasloff is a Professor in both the Department of Pediatrics and the Department of Surgery at Georgetown University School of Medicine and Director of Surgical Immunology of the Transplant Institute. Previously, Dr. Zasloff served as Georgetown’s Dean of Research and Translational Science responsible for management and strategic planning of a research enterprise involving \$130 million and more than 400 principal investigators engaged in basic and clinical research. He is author of more than 100 articles published in peer-review journals and has been assigned over 40 US and international patents.

Dr. Zasloff earned his BA *magna cum laude* from Columbia College and earned his M.D. and Ph.D. from the New York University School of Medicine. He also holds faculty positions at the University of Pennsylvania School of Medicine and Keio University Medical School located in Tokyo, Japan. Earlier in his professional career, Dr. Zasloff was Chief of the Human Genetics Branch of the National Institute of Child Health and Human Development of the National Institutes of Health, the Charles E.H. Upham Professor of Pediatrics and Genetics at the University of Pennsylvania School of

Medicine, and the Director of the Division of Human Genetics and Molecular Biology of the Children's Hospital of Philadelphia.

**About Immtech Pharmaceuticals, Inc.**

Immtech is a pharmaceutical company focused on the development and commercialization of new drugs to treat infectious diseases. Immtech has a well defined, expanding library of compounds targeting Hepatitis C, drug-resistant Gram-positive bacteria, fungal infections and other serious diseases. It is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat a range of disorders. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit the Company's website at <http://www.immtechpharma.com>

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the fiscal year ended March 31, 2008 being filed with the SEC on the date hereof, and in its other SEC filings and include, but are not limited to: (i) Immtech's ability to obtain additional funds; (ii) Immtech's ability to manage its remaining resources; (iii) Immtech's ability to continue as a going concern; (iv) Immtech's ability to retain key personnel; (v) the ability of Immtech's scientists and collaborators to discover new compounds; (vi) the availability of additional research grants; (vii) Immtech's ability to obtain regulatory approval of its drugs candidates; (viii) the success of Immtech's clinical trials; (ix) dependence upon and contractual relationship with partners; (x) Immtech's ability to protect its intellectual property; and (xi) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation, to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.

###